Kymera Therapeutics, Inc. (KYMR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics using targeted protein degradation (TPD). The company has no approved products and generates revenue solely through collaboration agreements. As of June 30, 2025, the company had 71,497,597 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Collaboration Revenue | $11,476 | $25,650 | $33,576 | $35,937 |
| Net Loss | $(76,614) | $(42,062) | $(142,195) | $(90,619) |
| Loss Per Share (Basic/Diluted) | $(0.95) | $(0.58) | $(1.77) | $(1.26) |
| Research & Development Expenses | $78,388 | $59,202 | $158,643 | $108,021 |
| General & Administrative Expenses | $17,645 | $17,373 | $33,916 | $31,747 |
| Cash, Cash Equivalents & Marketable Securities | $963,075 (as of June 30, 2025) | |||
| Accumulated Deficit | $(896,805) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by 55% in Q2 2025 compared to Q2 2024 ($11.5M vs. $25.7M). This decrease is primarily due to the recognition of revenue from the Sanofi collaboration, which varies based on the satisfaction of performance obligations.
- Increased Operating Expenses: Total operating expenses increased by 25% in Q2 2025 ($96.0M vs. $76.6M). R&D expenses rose by $19.2M, driven by a $10.5M increase in costs for the STAT6 program and increased personnel and facility costs.
- Widened Net Loss: Net loss increased by 82% in Q2 2025 ($76.6M vs. $42.1M) due to lower revenue and higher operating expenses.
- Capital Raise: In June 2025, the company completed a follow-on public offering, issuing 5,044,500 shares and pre-funded warrants, raising approximately $250.8 million in gross proceeds (initial closing). Subsequent exercise of the underwriters' option in July 2025 raised an additional $37.6 million.
- New Collaboration: On June 25, 2025, Kymera entered into an exclusive option and license agreement with Gilead Sciences for CDK2 degraders, receiving a $40.0 million non-refundable upfront payment. This amount is recorded as deferred revenue.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes that existing cash, cash equivalents, and marketable securities ($963.1 million as of June 30, 2025), plus proceeds from the June 2025 offering and the Gilead upfront payment, will fund operations into the second half of 2028.
- Pipeline Updates:
- STAT6 (KT-621): In early clinical development (Phase 1b) for Atopic Dermatitis. Costs increased significantly.
- IRAK4: Sanofi exercised its full participation election to advance the next-generation degrader KT-485 into clinical testing and intends to stop development of KT-474.
- IRF5 (KT-579): Lead molecule announced in May 2025; currently in IND-enabling studies.
- TYK2 (KT-295): In May 2025, the company decided not to advance this program into clinical development to prioritize other immunology programs and extend cash runway.
- Risks:
- Capital Needs: The company anticipates continued losses and will require substantial additional funding to complete clinical trials and commercialization.
- Development Uncertainty: As a clinical-stage company, there is no guarantee that product candidates will achieve regulatory approval or commercial success.
- Collaboration Dependence: Future revenue is heavily dependent on the success of collaborations with Sanofi and Gilead, including the exercise of options and achievement of milestones.
- Regulatory & Geopolitical: Risks include potential changes in FDA policies under the new 2025 administration, trade tariffs, and global economic instability.
Key Facts for Investor Verification
- Cash Runway: Verify the specific assumptions used to project funding sufficiency through the second half of 2028, particularly regarding the burn rate of the expanded STAT6 program.
- Gilead Agreement Terms: Review the specific milestones and option exercise conditions in the new Gilead agreement to understand the probability of realizing the potential $665 million in milestone payments.
- Sanofi IRAK4 Transition: Confirm the timeline and financial implications of Sanofi's decision to discontinue KT-474 in favor of KT-485 and how this impacts revenue recognition.
- TYK2 Discontinuation: Assess the impact of halting the TYK2 program on the overall pipeline strategy and resource allocation.
- Deferred Revenue: Monitor the recognition schedule of the $40 million Gilead upfront payment and remaining Sanofi deferred revenue.